Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $38.80 Consensus PT from Analysts
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) has earned an average recommendation of “Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in […]
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) has earned an average recommendation of “Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in […]
